《辉瑞制药（Pfizer）2023年影响力报告（英文版）（84页）.pdf》由会员分享，可在线阅读，更多相关《辉瑞制药（Pfizer）2023年影响力报告（英文版）（84页）.pdf（84页珍藏版）》请在三个皮匠报告上搜索。

1、2023Impact ReportPfizer 2023 Impact Report2IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceIntroductionGovernanceSocialEnvironmentAppendixESG PerformanceWhere to find more information2023 Annual Documents2023 Annual Review2023 Annual Report on Form 10-K2024 Proxy StatementIntroductionG

2、overnanceEnvironmentSocialESG PerformanceAppendix04-A Letter from Our Chairman&CEO05-A Message from Our Lead Independent Director06-2023 Progress and Highlights07-Our Approach to ESG08-ESG Priorities09-Our Stakeholders10-Spotlight Stories13-Governance of ESG14-Ethics,Transparency,Quality23-Accountab

3、ility26-Climate Change29-Sustainable Medicines32-Innovation and Global Health34-Equitable Access and Pricing38-Our People44-Governance45-Environment47-Social55-Global Reporting Initiative(GRI)Index71-Sustainable Accounting Standards Board(SASB)Index76-Task Force on Climate-Related Financial Disclosu

4、res(TCFD)82-About This ReportIn this ReportPfizer 2023 Impact Report3IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceIntroductionGovernanceSocialEnvironmentAppendixESG PerformancePfizer is a global biopharmaceutical company focused on advancing our Purposebreakthroughs that change pati

5、ents lives.Its our ambition to change a billion lives a year by 2027.Our Purpose Blueprint guides our strategy,and our core ValuesCourage,Excellence,Equity,and Joyguide our decision-making and how we do business.This report provides an overview of Pfizers Environmental,Social and Governance(ESG)prio

6、rities and goals,aimed at contributing to long-term value creation and a sustainable,responsible,and patient-centric business model aligned to our Purpose.The updates included cover the fiscal year from January 1,2023 to December 31,2023.For more information,please see About This Report on page 82.I

7、ntroductionPfizer 2023 Impact Report4IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceIntroductionAs Pfizer embarks on our 175th year of operations as one of the worlds most trusted and innovative healthcare companies,we are determined to outdo yesterday by remaining committed not only

8、to advancing our Purpose,but to being a good corporate citizen.I am proud to present Pfizers 2023 Impact Report.It reflects our dedication to being a force for good in the world by acting with integrity,holding ourselves to high standards,being accountable to our commitments,and addressing shortcomi

9、ngs candidly and with specific plans for improvement.We are mindful of the impact a company of our size and scale has on the planet and are working hard to be sure it is a positive one in every respect.In working to create a more sustainable future for all,we recognize that we are operating in an ev

10、er-changing world,and that our stakeholders expect us to step up and take action against that which threatens human health and the health of our planet.Whether that comes in the form of extreme weather events caused by climate change,social unrest,inequality,or other external factors,we at Pfizer be

11、lieve we have an obligation to bring our resources to bear to help solve such problems.Pfizers track record in the environmental,social and governance(ESG)space is strong.We look forward to continuing to build on it.Simply,our company has a conscience.We take seriously our obligation to conduct ours

12、elves in a way that makes the world a better place.Discovering,manufacturing,and delivering innovative vaccines and medicines is only part of what we contribute to society.This Impact Report and our accomplishments give me great pride.I am excited about what we will accomplish going forward.As alway

13、s,I am deeply grateful to my colleagues,partners,and stakeholders for their shared commitment to our Purpose.Together we can achieve great things and make a meaningful difference in the health of people and our planet.A Letter from Our Chairman&CEODr.Albert Bourla Pfizer Chairman&Chief Executive Off

14、icerPfizer 2023 Impact Report5IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceIntroductionI would like to express my gratitude on behalf of the Board of Directors for your interest in Pfizers ESG priorities and goals.Pfizers commitment to its Purpose Breakthroughs that change patients

15、livesis crucial for the companys long-term value creation and its dedication to a sustainable,responsible,and patient-centric business model.How Pfizer advances innovation to positively impact patients,global health,and society remains important to stakeholders and is a key focus for the Board as we

16、 oversee the companys progress in achieving its ESG goals.The Governance&Sustainability Committee(G&S Committee)of the Board is responsible for overseeing Pfizers ESG strategy,risk management,reporting,and practices.Additionally,and as detailed in this Impact Report,our other Board Committees overse

17、e specific elements of ESG associated with their respective areas of responsibility and risk oversight.Throughout 2023,the G&S Committee received regular updates from the Chief Sustainability Officer and other leaders about Pfizers progress towards advancing its ESG priorities and public commitments

18、 to climate sustainability and colleague diversity,equity,and inclusion.The Committee then shared this information with the Board.The Committee was also kept informed about potential changes within the dynamic external ESG landscape,stakeholder expectations,and new ESG reporting requirements.I know

19、that all of us on the Board take pride in serving on the Board of a company that recognizes the importance of long-term sustainability and is committed to advancing innovation responsibly and acting with integrity as it delivers on its Purpose.We are pleased to share Pfizers progress on these effort

20、s in this report and appreciate your interest.A Message from Our Lead Independent DirectorShantanu NarayenLead Independent Director Pfizer 2023 Impact Report6IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceIntroduction2023 Progress and HighlightsNet Zero StandardAiming to achieve by 20

21、40,which is 10 years earlier than expectations of the standard“Worlds Most Ethical Companies”and“Ethisphere”names and marks are registered trademarks of Ethisphere LLC.Recognized at the Leadership Level for our CDP Climate Change Disclosure13.9%Reduction in Scope 1&2 greenhouse gas(GHG)emissions fro

22、m 2019 baselineSee footnotes within the ESG Performance section for more details.Science Will WinSeagen Inc.integration to bring the best of the outside in as we focus on delivering transformative cancer therapies4 out of 12 members of the Board of Directors are women3 out of 12 members of the Board

23、 of Directors are ethnically diverse44.8%Representation for women at VP+levels globally30.5%Representation for U.S.minorities at VP+levelOver 40K Pfizer leaders have ESG KPIs factored into their compensation38%Pfizer New Molecular Entity and novel biologic applications approved by the FDA between 20

24、19-2023 designated as Breakthrough TherapiesNamed one of the Worlds Most Ethical Companies by Ethisphere for the third year in a rowPfizer 2023 Impact Report7IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceIntroductionWe apply science and our global resources to bring therapies to peop

25、le that extend and significantly improve their lives through the discovery,development,and manufacturing of medicines and vaccines.With senior leader support and collaboration at all levels,we aim to improve health outcomes,build trust,create shared value,and make a positive impact on society for ye

26、ars to come.Our Approach to ESG:Connected to Our Purpose and StrategyTrust is EverythingScience Will WinCourageExcellenceEquityJoyDisruption Calls for InnovationTime is LifeExecution Makes the DifferenceOur Core Business PrinciplesESG priority areas0102030405Our ValuesProduct innovationReducing cycl

27、e times,increasing success rates,and getting more breakthroughs into the hands of patients sooner.Climate changeTaking action to reduce our greenhouse gas emissions and mitigate risks associated with a changing climate.Equitable access and pricingExpanding affordable access to our breakthrough medic

28、ines and vaccines,and protecting people from the burden of infectious and other diseases.Product quality and safetyMaintaining a quality culture to ensure the highest priority is placed on the safety,efficacy,and reliability of our products,the safety of our patients and consumers,the quality of dat

29、a supporting regulatory submissions,and interactions with our stakeholders.Diversity,equity,and inclusionCreating opportunities to advance diversity,equity,and inclusion across our workforce,those with whom we do business,and society at large.Business ethicsExercising strong corporate governance and

30、 risk management practices to promote the long-term interests of our stakeholders.Pfizer 2023 Impact Report8IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceIntroductionESG PrioritiesPfizers ESG priorities were identified through an ESG priority assessment conducted in 2020.As part of t

31、he process we identified 30 key topics,which were mapped into six ESG priority areas.These priority areas are aligned with our Blueprint Strategy and are incorporated into our Enterprise Risk Management(ERM)process.EnvironmentSocialGovernancePrioritizeClimate changeColleague diversity,equity,and inc

32、lusionEquitable access and pricingProduct innovationBusiness ethicsProduct quality and safetyManageEnvironment and healthProduct end-of-lifeHealth,safety,well-beingHealthcare infrastructurePatient-centered designClinical trialsData privacyHuman rightsIP protectionSupply chain transparencyTransparenc

33、yMonitorPharmaceuticals in the environment Waste managementWater scarcity and dischargeDisease preventionEmployee developmentGlobal community investmentPartnershipsRetention and attractionBoard diversityLaws and regulations complianceLobbyingReliable supplyRight incentivesTopics that we give the mos

34、t prominence toPrioritizeManageMonitorTopics that we actively manage as a businessTopics that we monitor for a change in relative importancePfizer 2023 Impact Report9IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceIntroductionIn 2023,we continued to engage a variety of stakeholders to

35、inform our decision-making processes and provide us with insights as we work to advance our business responsibly.Patients and CaregiversPatients are our North Star.We work with patients and their caregivers to understand their needs and help ensure that our medicines and vaccines work to address the

36、m.As part of this,we engage with patients and patient advocacy groups to listen,learn,collaborate,and help address areas of unmet patient need and to incorporate their perspectives before we launch our medicines and vaccines.Shareholders and InvestorsOur shareholders,other stakeholders,and market an

37、alysts have a vested interest in Pfizers operations and the short-,medium-,and long-term success of the company.We engage investors on relevant issues,such as ESG,tax,patient access and affordability,and remuneration,through ongoing one-on-one conversations,surveys and questionnaires,and targeted co

38、mmunications,including ESG-related content on our Investor Insights website.ColleaguesWe want all our colleagues to develop,grow,and succeed,and we believe that everyone deserves to be seen,heard,cared for,and respected.We engage with colleagues to understand their perspectives and needs,conduct reg

39、ular surveys to understand colleague satisfaction and other aspects of corporate culture,and invest in programs to help colleagues manage their mental and physical well-being.Governments,Policymakers,and RegulatorsWe engage policymakers and regulators to understand the external challenges and regula

40、tory landscapes affecting patients,communities,and our commitment to our Purpose.Through ongoing two-way dialogue with policymakers and targeted one-on-one engagement with industry bodies,we guide our medicines from the laboratory to patients.PartnersThe scale of our ambition requires us to work in

41、coordination and collaboration with external partners.We engage with foundations,multilateral organizations,non-governmental organizations,and coalitions on issues including access to medicines and vaccines,environmental concerns,transparency,and business ethics.We engage suppliers to understand the

42、ir needs and support their efforts to reduce their environmental footprints.We work alongside global health and public health organizations to expand access to our medicines and vaccines,including on-the-ground support for health and education initiatives,and partner with academic and industry resea

43、rch alliances to help increase the number of future breakthroughs for patients.We also educate medical organizations about the latest research on our medicines and vaccines,our pipeline,and ways to access our products.Our StakeholdersPfizer 2023 Impact Report10IntroductionGovernanceSocialEnvironment

44、AppendixESG PerformanceIntroductionIn December 2023,Pfizer completed its acquisition of Seagen Inc.,a global biotechnology company that discovers,develops,and commercializes transformative cancer medicines.This acquisition is one of the largest investments in Pfizers history,with the goal of deliver

45、ing breakthroughs that improve the lives of people with cancer.Seagen is a world leader in AntibodyDrug Conjugates(ADC)technology,which is emerging as a powerful tool across a broad range of cancers designed to preferentially kill cancer cells and limit off-target toxicities.With the addition of Sea

46、gens four in-line medicines,Pfizers industry-leading Oncology portfolio now includes over 25 approved medicines and biosimilars across more than 40 indications,including nine medicines that are either blockbuster or have the potential to be blockbuster.As a result,Pfizers Oncology pipeline has doubl

47、ed in size with programs spanning multiple modalities,including ADCs,small molecules,biospecifics,and other immunotherapies1.Moving forward,Pfizer will leverage its leading protein engineering and medicinal chemistry capabilities to advance Seagens ADC technology,unlocking potential novel combinatio

48、ns and next-generation biologics.Driven by science and a passion for improving and extending patients lives,well continue to work with great urgency towards our common Purpose to deliver transformative cancer medicines and bring new hope to people living with cancer everywhere.We continue to pursue

49、breakthroughs in other areas as well.Innovating for patients is in our DNA,and were proud of key 2023 developments,including in the areas of vaccines against respiratory syncytial virus(RSV)and meningococcal disease,as well as treatments aimed at ulcerative colitis and alopecia areata.Spotlight Stor

50、iesThe stories that spotlight our extensive efforts in our priority areas.A New Chapter in the Battle Against CancerOur company Purpose guides our environmental sustainability priorities,with a focus on climate impact mitigation,conservation of resources,and the reduction of waste arising from our o

51、perations.We recognize the profound societal and public health impacts that may result from environmental issues,such as the potential for increased adverse impacts on human health and decreased access to critical medicines and vaccines due to disruptions in value chains caused by the greater freque

52、ncy of severe weather.In furtherance of our commitment to achieving the voluntary Net Zero standard by 2040,ten years earlier than the timeline described in the standard,and to achieve our goal of sourcing 100%renewable energy by 2030,in 2023 we executed renewable eletricity virtual power purchase a

53、greements(VPPAs)to cover the equivalent of Pfizers purchased electricity for its manufacturing,research and development(R&D),and commercial sites in the European Union.This solar capacity,together with the North America VPPA signed in 2021,will play a key role in advancing our ambitious climate goal

54、s.Advancing Net Zero for Patients and Planet1 As of December 14,2023.Pfizer 2023 Impact Report11IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceIntroductionArtificial Intelligence(AI)is transforming life sciences and has the potential to improve healthcare for patients across the globe

55、.It has the power to uncover and activate meaningful insights to revolutionize the pharmaceutical and healthcare industries.We recognize that AI can be a powerful technology in support of our mission to create breakthroughs that change patients lives,including by potentially accelerating R&D of new

56、medicines and vaccines and enhancing the manufacturing and delivery of therapies to patients.We have the obligation to use AI ethically,responsibly,and purposefully to benefit our patients,customers,colleagues,and society.Pfizers AI strategy is designed to enable us to responsibly and rapidly bring

57、breakthroughs to patients.Like everything we do,trust and integrity are core to our adoption of AI.This is the basis of our AI risk management program,overseen by a cross-functional AI Council,which includes AI principles,corporate policy,risk assessment,and enterprise controls.Our strategic risk ma

58、nagement approach and governance empower us to ethically and responsibly harness the power of AI in service of patients.We are pioneering the use of AI in pharmacovigilance the area of science in which scientists and medical professionals monitor medicine and vaccine-related safety issues.For exampl

59、e,we are testing the ability of AI to assess and categorize reports people file when they experience an“adverse event”(such as an unexpected side effect)in conjunction with a Pfizer product.This enables us to collect and analyze large amounts of data,presenting it to trained experts to view and act

60、upon more quickly to better meet patients needs.Spotlight StoriesOur work reflects the enduring belief that better health is possible for everyone,everywhere.As such,our commitment extends to partnering with stakeholders to provide access programs and services,innovative technologies,educational mat

61、erials,and more to support the patient journey.Patient Advocacy Organizations are our crucial partners in the advancement of patient-centered healthcare.We believe that with the right tools and resources,we can better support patient communities globally.Building on our longstanding engagement with

62、Patient Advocacy Organizations,in 2023,we were proud to launch a new initiative:the Patient Advocacy Leadership Collective.Co-created with patient advocacy leaders worldwide,we developed the Patient Advocacy Leadership Collective platform to support patient advocacy organizations around the world by

63、 empowering them with knowledge and skills through offering evidence-based tools and resources that elevate their work with patient communities.The Patient Advocacy Leadership Collective offers programs that can aid growth and development for patient advocacy organizations to deliver upon their miss

64、ion to support patients and their families.Responsible Artificial Intelligence Innovation for Patient ImpactForging the Patient Advocacy Leadership CollectivePfizer 2023 Impact Report12IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceIntroductionGovernanceSocialEnvironmentAppendixESG Pe

65、rformanceOur Purpose and values guide our ethical decision-making and how we deliver breakthroughs.Pfizer prioritizes integrity,safety,and quality as we advance innovation for patients and seek to improve global health.Our Board of Directors is actively engaged in the governance and oversight of our

66、 ESG strategy,which is aligned with our Purpose Blueprint strategy.13-Governance of ESG14-Ethics,Transparency,QualityEthical Decision-MakingLaws and Regulations ComplianceOpen Door Culture and InvestigationsSafety and QualityCounterfeit MedicinesSupply Chain TransparencyIntellectual PropertyClinical

67、 TrialsData Privacy and ProtectionHuman Rights and the Right to HealthPolitical Contributions and Lobbying Activities23-Accountability Right Incentives Board of Directors and Board Committees Board Leadership Structure Board Diversity and IndependenceHow our approach to governance issues supports th

68、e Sustainable Development Goals(SDGs)Good Health and Well-BeingWe aspire to ensure health and well-beingfor all through equitable access to medicinesand vaccines.Gender EqualityWe aim to end discrimination against women,ensure equal opportunities for leadership,and access to reproductive health.Resp

69、onsible Consumption and ProductionWe aim to achieve environmentally sound life cycle management and adopt sustainable practices.Climate ActionThrough our goals we are taking urgent action to help combat climate change and its impacts.Peace,Justice,and Strong InstitutionsWe operate to uphold justice,

70、promote the rule of law,and develop ethical,transparent,and representative decision-making.More information on the SDGs here.GovernancePfizer 2023 Impact Report13IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceGovernanceOur ESG efforts align with our commitment to achieving our Purpose

71、 and supporting the communities in which we live and work through ethical decision-making based on our core values:Courage,Excellence,Equity,and Joy.Values-based decision-making promotes accountability and helps ensure that integrity,quality,safety,and ethics are integrated in all we do.Pfizers gove

72、rnance of its ESG prioritiesaligned with our Blueprint strategyis critical to help enable impact,innovation,and transparent reporting.Our ESG governance is built on the principles of oversight by our Board of Directors,commitment by and accountability of leadership,and colleague engagement across th

73、e company.Additionally,we leverage diverse perspectives from internal and external stakeholders to inform our ESG strategy and priorities.ESG at Pfizer is governed by our Sustainability Steering Committee,chaired by our Chief Sustainability Officer,which has responsibility for considering and adopti

74、ng potential goals,commitments,and targets with input from experienced subject matter experts and advisors.The Committee advises on key issues and guides the integration and implementation of Pfizers non-financial,ESG reporting.This Committee is overseen by the Executive Sustainability Committee,cha

75、ired by the Executive Leadership Team member leading Corporate Affairs(this leader reports directly to the Chairman and CEO),with escalation to the Governance&Sustainability Committee(G&SC)of the Board of Directors,as appropriate.The Board of Directors is engaged in and supports ESG at Pfizer.The G&

76、SC is primarily responsible for oversight of our ESG strategy,reporting,policies,and practices.The G&SC regularly receives updates from management on Pfizers progress as measured against the companys ESG strategy,metrics,and goals.The G&SC also receives updates on the regulatory environment that may

77、 impact our ESG strategy and reporting requirements.The G&SC has oversight of human capital management,including succession planning;culture;diversity,equity and inclusion;pay equity;talent management;political and lobbying activities;climate change program;reputational risk factors;and Board divers

78、ity.Other Board Committees oversee elements of our ESG program associated with their respective areas of responsibility.For example:The Audit Committee has primary responsibility for overseeing Pfizers ERM program and reviews and receives briefings on priority issues that fall under ERM and ESG,incl

79、uding company culture(compliance related concerns,workplace behavior,harassment,and retaliation).The Compensation Committee oversees the executive compensation program(which includes an“ESG Scorecard”to align funding of our annual short-term incentive plan for over 40,000 eligible global colleagues

80、and leaders,in part,to select social and environmental key performance indicators(KPIs),please see Right Incentives for more information),including approving compensation of our executive officers.The Compensation Committee also has oversight of human capital management,which may include executive d

81、iversity,pay equity,inclusion,recruiting,retention,career development,and succession planning(in collaboration with the G&SC).See Pfizers 2024 Proxy Statement for further details on the executive compensation program.The Regulatory and Compliance Committee oversees the compliance program,ethics and

82、integrity(including company culture),product quality and safety,the quality and compliance governance framework,and risk management,in addition to overseeing healthcare-related regulatory and compliance risks in connection with the development,manufacture,supply,and marketing of products and risk mi

83、tigation efforts.We encourage all colleagues to contribute to achieving our ESG goals by understanding our priorities and advancing business in a sustainable,responsible way in their day-to-day activities.We integrate ESG by partnering closely with colleagues in our priority areas to establish ESG g

84、oals and define action plans to achieve those goals.Governance of ESGPfizer 2023 Impact Report14IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceGovernanceAt Pfizer,trust is everything.Our patient-centric Purpose and culture of quality,integrity,and safety are of paramount importance as

85、 we innovate and continue to deliver breakthroughs.Our leaders set the tone for our strong culture of integrity and encourage colleagues raising concerns to speak up without fear of retaliation.Ethical Decision-Making Values-based decision-making promotes accountability and helps ensure that integri

86、ty,quality,safety,and ethics are foundational to all we do.Our Code of Conduct(the Blue Book)and related policies,procedures,and training are designed to support compliance and adherence to our values-Courage,Excellence,Equity,and Joy.Policies governing colleague interactions with healthcare organiz

87、ations,physicians,patients,and other stakeholders are contained in the White Guide for U.S.headquarters-based colleagues and the Orange Guide for U.S.field-based colleagues.Pfizer also maintains a Global Policy on Interactions with Healthcare Professionals,including ethical marketing.We incorporate

88、ethics and business integrity expectations into internal performance management frameworks and assessments,which are designed to foster colleague accountability,including leadership.Our“Integrity in Hiring”initiative implemented in select markets in 2023 incorporates ethics and compliance into the h

89、iring process through interview questions and evaluations.TRANSPARENCY We are committed to the principle of transparency.We uphold high ethical,scientific,and medical standards in our R&D activities and are committed to disclosing financial and other interests and relationships that may create appar

90、ent or perceived conflicts of interest.These include areas such as funding for educational activities,the status of our U.S.pharmaceutical post-marketing commitments,our pipeline of experimental medicines,the registration and reporting of clinical trial results,corporate political contributions in t

91、he U.S.,U.S.federal and state lobbying activities,and disclosures of medical grants.Pfizer also reports to the Centers for Medicare and Medicaid Services(CMS)payments and other transfers of value made to U.S.-licensed physicians and U.S.teaching hospitals.Laws and Regulations Compliance Our ethics a

92、nd compliance program is structured around eight fundamental elements,which form the framework for effective compliance and quality risk management.Quality,integrity,and proactive risk management drive our efforts to enable innovation for patients and global health.Pfizers integrity and compliance e

93、xpectations represent a shared undertaking and put responsibility on all colleagues.Pfizer is committed to conducting business responsibly and acting ethically,in accordance with all applicable laws and regulations.We expect the same commitment to integrity and compliance from suppliers,as well as f

94、rom consultants,agents,representatives,and other third parties acting on our behalf,as well as those acting on their behalf(e.g.,subcontractors)in connection with work for Pfizer.Pfizers Chief Compliance,Quality&Risk Officer reports to the CEO and is a member of the Executive Leadership Team.This st

95、ructure is designed to ensure direct access to leadership,sufficient resourcing,and independent execution of responsibilities.Our program is supported by full-time colleagues as well as a network of colleague“compliance champions,”who serve as both models and resources helping to drive business-led

96、quality and compliance ownership worldwide.The Regulatory and Compliance Committee of the Board of Directors oversees our quality and compliance governance framework,which supports the programs independence and risk management.This Committees oversight of healthcare quality and compliance covers the

97、 following areas in pursuit of advancing integrity and Pfizers Purpose:business ethics;quality and integrity in the discovery,development,manufacturing,and delivery of vaccines and medicines;responsible product marketing;third-party risk management;and compliance with anti-bribery/anti-corruption,tr

98、ansparency,product promotion,and other applicable laws and regulations.The Quality and Risk Committees for our core functional areas provide an innovative framework to advance business-led,proactive risk management and drive clear accountability for acting with integrity.These committees report up t

99、o our Executive Compliance Committee,the highest-levelEthics,Transparency,QualityPfizer 2023 Impact Report15IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceGovernanceinternal compliance oversight body,which is composed of Pfizers executive leadership and the Head of Corporate Audit,and

100、 chaired by the CEO.This Committee has a remit similar to that of the Regulatory and Compliance Committee of the Board.We regularly engage independent third parties to assess our ethics and compliance program against standards established by governments and industry best practices.In 2023,we engaged

101、 a third party to conduct an independent compliance program review to assess program effectiveness and identify opportunities for continuous learning and enhancement.Our internal audit function has a systematic and regular audit process that annually assesses our operations.Additionally,in coordinat

102、ion with the Legal and Compliance Divisions and the Quality and Risk Committees,internal audit works with key stakeholders across the company to conduct our ERM process that annually identifies,assesses,and manages risk priorities.Those priorities extend to cover quality,compliance and ethical stand

103、ards,responsible marketing,and antibribery/anti-corruption.We are committed to integrating integrity and quality into everything we do,as well as to deterring non-compliance and driving ethical behavior.Our robust,proactive quality and compliance governance framework is built around the elements of

104、effective quality,compliance,and risk management,including,for example:Culture:Leaders are committed to and accountable for fostering a culture consistent with our values,including psychological safety to support colleagues in speaking up or raising concerns without fear of retaliation and promoting

105、 continuous improvement.We hold managers accountable and expect them to play a key role in cultivating this speak-up culture and reinforcing that acting with integrity is everyones responsibility;we provide managers with supporting materials and templates that can be customized for local,market-spec

106、ific use.Policies:Clear,easy-to-understand policies and procedures provide guidance,including our principles-based Code of Conduct(available publicly in over 30 languages)and our whistleblower policy to protect colleagues who raise concerns,as outlined in our Code of Conduct.Training:Colleagues and

107、certain third parties receive risk-based,role-specific training on our Code of Conduct and other key areas,including ethical standards,responsible marketing and advertising practices,information security,safety reporting responsibilities,and anti-bribery/anti-corruption,upon hire and regularly there

108、after(in general every one to two years).Our ethics and compliance training programs use multi-modal components to address different learning styles,maximize engagement,and reinforce salience of training content.Our training program encompasses a role-based scope of topics and depth of knowledge ass

109、essments to help drive training effectiveness.Communications:Messaging about integrity,including communications reinforcing expectations from leadership,culture campaigns,and creative use of various media,reinforces our focus on always doing things the right way and speaking up with questions or con

110、cerns.Our communications plans are designed to cultivate a culture of integrity throughout the company,including by addressing global,functional,and regional priorities,and existing and emerging training,culture,and communication needs.Ethics,Transparency,Quality-continuedPfizer 2023 Impact Report16

111、IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceGovernance Risk Assessment&Mitigation:Enterprise-level and tailored quality and compliance risk assessments,including in the area of anti-bribery/anti-corruption,are conducted regularly(on a market-by-market basis and within and across ou

112、r core functions).These assessments inform our annual ERM process aimed at identifying,assessing,prioritizing,and mitigating priority and emerging risks.It enables enhanced oversight and appropriate resourcing to proactively manage risks.We seek to identify and address risks as early as possible,pre

113、venting non-compliance proactively,where possible.Monitoring:Live,continuous monitoring across key risk areas is designed to detect and remediate any potential non-compliance and identify opportunities for program enhancement,risk mitigation,and continuous learning.Third Party Management:Robust cont

114、rols and processes are designed to evaluate and mitigate risk related to third parties we work with,including a formal global anti-bribery/anti-corruption diligence process that includes screening,auditing,training,confirmation of policies(including bribery/corruption prohibitions),and monitoring of

115、 third-party agents and intermediaries,and other risk-based compliance controls designed to ensure ethical business practices and compliance with applicable laws and regulations,including anti-bribery/anti-corruption laws.ANTI-BRIBERY AND ANTI-CORRUPTION(ABAC)Our international anti-bribery and anti-

116、corruption policies and procedures are designed to ensure compliance with the U.S.Foreign Corrupt Practices Act(FCPA)and applicable international anti-bribery laws.Pfizer policy,also known as“My Anti-Corruption Policy and Procedures”(MAPP),prohibits all forms of bribery and corruption,whether by col

117、leagues or our business partners.Colleagues and business partners must never offer,promise,authorize,or provide a payment or benefit that is intended to improperly influence a government official,healthcare professional,or any other person,including commercial entities and individuals,in exercising

118、their responsibilities.Learn more about Pfizers ABAC program here.Open Door Culture and Investigations Leaders and management are dedicated to fostering a culture in which all colleagues can ask questions,raise concerns,and report potential misconduct without fear of retaliation.We measure colleague

119、 comfort and awareness about raising concerns,including awareness of our whistleblower policy,through our confidential enterprise Pfizer Pulse Engagement Survey sent to all colleagues annually.The survey results are used to focus leadership communications,training,and other proactive efforts to fost

120、er our Purpose-driven culture and encourage speaking up.Many channels exist for raising questions and reporting concerns,including the Compliance Helpline(third-party public hotline available by phone or web,in over 30 languages,with anonymous reporting where allowed under local law),the Compliance

121、Division(through email,phone,fax,mail,and directly to colleagues),management,and other channels supported by our Open Door Policy(which includes our whistleblower policy).This policy encourages colleagues to present ideas,ask questions,and raise concerns.Retaliation against anyone who seeks advice,r

122、aises a concern,reports misconduct,or provides information in an investigation is strictly prohibited by our policy that protects whistleblowers.In addition,our Ombuds Office is an available resource to support colleagues with information and guidance to help them resolve work-related issues.Pfizer

123、takes reports of known or suspected violations of company policies and applicable law seriously;our goal is to respond appropriately and promptly to all questions and reported concerns.We aim to identify and address any potential inappropriate conduct as early as possible,prevent future recurrences,

124、and inform continuous improvement.We investigate all referable compliance issues(RCIs)significant potential,suspected,or actual violations of law or policy.For RCIs where there is a substantiated violation,we institute individual discipline where appropriate,including measures such as coaching,warni

125、ngs,and termination.Our compliance investigations process also includes analysis of the root cause of substantiated RCIs.After investigation,we work with accountable stakeholders to implement corrective and preventative actions.We monitor the effectiveness of these actions,adjust as needed,and track

126、 and report on progress.Pfizer has a process to escalate certain significant matters to the Executive Compliance Committee and the Regulatory and Compliance Committee and Audit Committee of the Board.Ethics,Transparency,Quality-continuedPfizer 2023 Impact Report17IntroductionGovernanceSocialEnvironm

127、entAppendixESG PerformanceGovernanceSafety and QualityPatient health and safety are foundational to everything we do.We are committed to ensuring that our products are developed,manufactured,and supplied to high standards of quality,safety,efficacy,and are assured through the deployment of our robus

128、t Quality Management System(QMS).Patient-Centric Focus Patient health and safety comes first in our work from early-stage R&D through the full product lifecycle.Our patient-centric approach to R&D begins in the lab with data modeling to determine potential therapies.Our clinical trials(page 21)are d

129、esigned around patient safety with equitable and inclusive participation.Our global supply network manufactures and delivers products pursuant to our robust policies and procedures designed to ensure safety and quality in accordance with Pfizers Global Quality Standards and relevant regulations,incl

130、uding Good Manufacturing Practices(GMP).Our policies and procedures are based on industry best practices and reflect Pfizers own high standards.Each of our internal manufacturing,supply,and distribution operations,as well as our external vendors,hold relevant manufacturing licenses/certifications in

131、dicating compliance with GMPs.Our quality performance is actively monitored through an integrated management system to identify and mitigate risks.Throughout each products lifecycle,we continuously monitor and evaluate all relevant safety and quality information,including complaints and adverse even

132、ts.This monitoring enables proactive,data-driven actions related to patients,consumers,healthcare professionals(HCPs),investigators,institutional review boards/independent ethics committees(IRBs/IECs),Data Monitoring Committees(DMCs),and health authorities and regulators in accordance with both inte

133、rnal and external standards.Quality Management System(QMS)Pfizers QMS,as defined in our Corporate Quality Policy,provides an integrated framework through which Pfizer achieves its quality and safety standards.This framework is based on industry-recognized quality management principles.The QMS is des

134、igned and built to adhere to applicable standards and requirements of health authorities and global regulators,such as:International Organization for Standardization(ISO)13485;Good Practices(GxP)such as Good Laboratory Practices(GLP),Good Clinical Practices(GCP),Good Manufacturing Practices(GMP),Goo

135、d Distribution Practices(GDP),and Good Pharmacovigilance Practices(GPvP);and International Council for Harmonisation(ICH)of Technical Requirements for Pharmaceuticals for Human Use guidelines.The QMS covers pharmaceuticals,vaccines,medical devices,and in-vitro diagnostic products,in addition to focu

136、sing on:Research and development of products Clinical trial design and execution Regulatory submissions Manufacturing,packaging,and distribution and supply of products,including raw materials procurement Pharmacovigilance(PV)and post-market surveillance Commercial and medical affairs activities This

137、 framework embeds quality management throughout the organization and is enabled by a governance structure with clear policies,communications,and escalation pathways.Our QMS is continuously monitored to drive innovation and agility,while helping to ensure the timely identification and appropriate act

138、ioning of quality,safety,and compliance issues.Quality and Integrity Culture Pfizer places great emphasis on maintaining a culture of quality and integrity.Throughout the year,colleagues at all levels contribute to the development and implementation of Quality&Integrity(Q&I)culture initiatives,which

139、 serve to reinforce the importance of product quality and safety while also fostering a culture of integrity.An example of one such initiatives is the appointment of Q&I Championsindividuals nominated to act as culture ambassadors.These champions encourage open communication,proactive risk managemen

140、t,and speak-up behavior at all levels.Q&I Champions foster this culture through colleague empowerment,peer-to-peer assistance,education,and open dialogue.Our quality and integrity culture is actively monitored,improved,and sustained through our QMS.Ethics,Transparency,Quality-continuedPfizer 2023 Im

141、pact Report18IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceGovernanceTraining and Qualification Our comprehensive global training and qualification policies and procedures are designed to ensure compliance with our scientific,ethical,legal,and regulatory obligations,as well as our ow

142、n high standards.Requirements are in place to help ensure all individuals(based on role and responsibility)who perform work for or on behalf of Pfizer have the appropriate education,training,and resources to work in compliance with applicable laws,regulations,and Pfizer policies.Training compliance

143、is actively monitored and formally documented.Risk and Issue Management Pfizers Risk Management Framework is a systematic,continuous,end-to-end process for identifying and mitigating quality and compliance risks.It provides criteria to conduct risk assessments grounded in defined thresholds for esca

144、lation,which are routinely tracked and monitored.The framework enables timely notification to management of critical issues and significant trends,and implementation of corrective and preventative actions.Third Party Management Pfizers global QMS framework is designed to ensure that third-party part

145、ner materials and services meet our exacting product quality standards,spanning the full product lifecycle including R&D,clinical research,manufacturing,and distribution.Pfizer recognizes the strategic importance of Contract Manufacturing Organizations(CMOs)and Contract Research Organizations(CROs).

146、As such,Pfizer has dedicated teams to maintain the necessary policies and effectively identify and mitigate associated risks.Processes are in place for the management and oversight of external parties who carry out work on Pfizers behalf to assure control of outsourced activities and compliance with

147、 applicable laws,regulations,and Pfizer policies.We are committed to selecting companies that are responsible,ethical,and reliable partners.The performance of these partners is monitored,including through regularly conducted audits.Audit outcomes are used to drive continuous improvement in both perf

148、ormance and compliance.Please see page 19 for more information on Supply Chain Transparency.Audits and Inspections As part of our independent audit program,we regularly assess the effectiveness of our QMS.Pfizers internal audit processes are conducted in accordance with all applicable regulatory req

149、uirements,standards,guidelines(e.g.,ISO&ICH),and governing GxPs,to help ensure patient safety,product quality,and applicable licenses and certifications are maintained.The audit program spans preclinical,clinical,pharmacovigilance,regulatory,medical,manufacturing and logistics,suppliers,and postlaun

150、ch activities,including responsible marketing and ethical product promotion.The program also covers regulated processes and information technology controls.Our audits are designed to provide assurance that we are compliant with regulatory requirements worldwide and our own standards.This helps ensur

151、e that we proactively identify and remediate risks to compliance.Finally,we routinely undergo GMP,GCP,and PV inspections from regulatory agencies worldwide.Continuous Improvement(CI)At Pfizer,we pursue innovation and continuous improvement in our work across the enterprise,including through CI initi

152、atives such as:Implementation of a next-generation digital quality management system Increased efficiency and effectiveness of Pfizers quality lab practices and safety systems Increased use of advanced analytics and AI in Pfizers manufacturing and supply chain networks Improvement of our quality and

153、 risk management systems and tools to adapt to changes in the external environment and internal strategy Continuous enhancement initiatives for medical devices and combination products focused on user requirements,integration of cutting-edge technology,and alignment with Net Zero initiativesWe have

154、a comprehensive quality and compliance governance process in place through which product quality and safety indicators are reported on,evaluated,and actioned as appropriate.We are committed to transparently communicating key product quality and safety indicators including the following metrics.GCP-G

155、ood Clinical Practices GMP-Good Manufacturing Practices PV-Pharmacovigilance VAI-Voluntary Action Indicated(U.S.FDA)OAI-Official Action Indicated(U.S.FDA)Note:Does not include Seagan Inc.data1 Count of internal audits includes all Pfizer audits performed of a Pfizer clinical/GMP/PV facility and/or p

156、rocess Count of third-party audits includes all Pfizer audits performed of an external clinical/GMP/PV vendor,clini-cal site,or contract manufacturing organization(CMO)3 Count of inspections includes all GCP/GMP/PV inspections of Pfizer listed below:GCP:Investigator sites,sponsor,vendors/CROs that a

157、re involved with a Pfizer product or process GMP:Pfizer Global Supply(PGS)sites,PharmSci sites,Pfizer Country Offices(PCOs),Distribution/Logistics Centers(LC),SLS(Labs),Quality Centers PV:Sponsor,vendors that are involved with a Pfizer product or process4 Data includes both regulatory warning letter

158、s as well as enforcement actions(e.g.,seizure,injunction,criminal prosecution and/or criminal fines for food,drug,and cosmetic act violations)5 Definition of Recall ClassificationsEthics,Transparency,Quality-continuedSafety and Quality KPIs2023#Internal Audits across GCP/PV/GMP176#Third Party Audits

159、 across GCP/PV/GMP2995#GCP/GMP/PV FDA Inspections350#GCP/GMP/PV Inspections from All Other Health Authorities3160#Unique Health Authorities Completing Inspections63#FDA inspections that resulted in an enforcement action40#GMP Inspections resulting in VAI status20#GMP Inspections resulting in OAI sta

160、tus0#GCP Inspections resulting in VAI status2#GCP Inspections resulting in OAI status0#PV Inspections resulting in VAI Status0#PV Inspections resulting in OAI Status0#FDA Recalls54%of batches distributed with no recalls(U.S.Market)99.9%#Class I Recalls3#Class II Recalls0#Class III Recalls1Pfizer 202

161、3 Impact Report19IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceGovernanceCounterfeit Medicines Counterfeit medicines pose a significant risk to patient health and safety.To protect our patients,we take a proactive approach to product safety by investing in an enterprise strategy to c

162、ombat counterfeit threats through patient education,legislative advocacy,surveillance,and interdiction1.Additionally,we are building a coalition with healthcare providers and associations,policy leaders,regulatory agencies,distributors,insurers,pharmacies,patient advocacy groups,and other pharmaceut

163、ical companies to combat the risk counterfeits pose to the health of patients and communities.This is formalized in our DETECT,DISRUPT,DETER,and IMPACT framework in our campaign against counterfeit Pfizer medicines.Pfizer has continued to strengthen its partnerships with external stakeholders,a tran

164、sformative factor in the ongoing battle against counterfeit medicines.On August 10,2023,the U.S.Customs and Border Protection(CBP)and the U.S.Chamber of Commerce renewed a memorandum of understanding(MOU)to enhance intellectual property rights enforcement through information sharing.The MOU,initiall

165、y signed in 2021,now renewed for a period of five years,represents a groundbreaking framework for collaboration between the public and private sectors in combating counterfeits.Pfizer played a leading role developing this initiative and participated in the data sharing pilot program,yielding patient

166、-protecting law enforcement results.Pfizer routinely provides training to policy makers and law enforcement,supporting their ability to identify counterfeit drugs and combat counterfeiting.In 2023,we scaled the“No Fakes for Health Sake”educational campaign to markets outside the U.S.The campaign,whi

167、ch aims to raise awareness of the dangers of counterfeit medicines among patients,healthcare providers(HCPs),pharmacists,policy makers,and government officials,is available in multiple languages to further maximize its reach.Our“Counterfeit Medicines:A Serious Threat to Patient Safety”toolkit serves

168、 multiple stakeholders who join the fight against counterfeits.Resources on how to safely buy medicines online are available at our corporate website at P addition to our traditional anti-counterfeit efforts,Pfizer helps address illicit online prescription drug offers through advanced internet monit

169、oring anddisruption programs.We search and systematically disrupt online pharmacy and social media groups dispensing counterfeit versions of Pfizer medicines and vaccines with enhanced digital tools that keep pace with the sophisticated and rapidly evolving tactics employed by counterfeiters to targ

170、et patients.We employ technological advancements and innovations to help ensure our efforts are adapting to the evolving landscape in this fight against counterfeit medicines.If a counterfeit product is identified in the legitimate supply chain,a formal process is in place to alert the appropriate a

171、uthorities and relevant trading partners.Additionally,we collaborate with distributors and repackagers to monitor distribution channels and improve surveillance.Pfizer evaluates and invests in packaging and information technologies to align with global serialization regulations and challenges associ

172、ated with counterfeiting,theft,and diversion.The unique Product Identifiers developed for serialization will enable the tracking and tracing of product movement through the supply chain,from the manufacturing site to patient dispensation(including Government Systems and Trading Partners)and will all

173、ow authorized trading partners to verify the authenticity of our medicines with a simple scan.Supply Chain Transparency We set high standards for responsible supply chain management,guided by robust governance processes.This helps ensure the safety and quality of the medicines and vaccines we produc

174、e and aligns with our core value of Equity.Compliance with laws is our baseline expectation,and we also establish other risk-based assessment criteria to help assure our suppliers are responsibly managing environmental,health,and safety(EHS)risks and maintaining a robust supply chain.Our established

175、 risk-based evaluation of suppliers,including contract manufacturers,assesses EHS and sustainability performance.Evaluations include engagement with suppliers to help support their efforts to improve EHS,sustainability,and labor and human rights performance.We apply a risk-based approach to determin

176、e where to complete our evaluations and apply our efforts where we believe there is opportunity to make the greatest potential impact and drive improvement.Our collaborations with our suppliers are focused on compliance with laws,improving sustainability of operations,and alignment to our Supplier C

177、onduct Principles and the Pharmaceutical Supply Chain Initiative(PSCI)Principles for Responsible Supply Chain Management.Please see our Responsible Sourcing page for additional details.These reviews also integrate evaluation of human rights considerations aligned with SA 80002.Pfizer maintains a foc

178、used human rights diligence program as described in our Modern Slavery Statement,which outlines our management approach in our supply chain and our operations.Pfizer is currently focusing on targeted high-risk areas as identified by the Global Slavery Index and is taking steps to address these risks

179、 as described in our Statement,including implementation of our corporate labor and human rights standard.If we identify areas with higher risk,our process outlines additional due diligence actions to help us avoid being complicit in supporting modern slavery.Through a combination of remote and on-si

180、te audits,we assessed EHS performance for 109 supplier facilities in 2023,resulting in 878 observations.We require our suppliers to develop action plans in response to our audits and implement improved controls,as needed.Pfizer is a founding member and active participant in the PSCI.Pfizer colleague

181、s currently sit on the PSCI board and lead PSCI working committees.In 2023,Pfizer colleagues also supported PSCI capability-building initiatives by serving as speakers at supplier conferences.RELIABLE SUPPLYWe take action to help ensure the safe,secure,and compliant warehousing and transportation of

182、 Pfizer products.An important component of our commitment to patient safety is the reliable supply of medicines and vaccines.Our policies and expectations for those across our supply chain is that they adhere to relevant local and federal regulations,in addition to conforming to our own strict stand

183、ards and expectations of compliance excellence.Ethics,Transparency,Quality-continued1 In this context,“interdiction”refers to the seizure,raids,and arrests to prevent counterfeits from reaching their targeted audience.2 SA 8000 is an international certification standard that encourages organizations

184、 to develop,maintain and apply socially acceptable practices in the workplace.Pfizer 2023 Impact Report20IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceGovernanceSUPPLIER DIVERSITY IS IN OUR DNAPracticing inclusive sourcing is aligned to our Equity value.We are committed to having a s

185、upplier base that represents the diverse patients we serve.We believe that by working with diverse suppliers,we gain a fresh,innovative perspective that ultimately helps us better serve our patients.Our supplier diversity program focuses on providing equitable opportunities as well as mentoring and

186、spending with diverse and small owned businesses.The program prioritizes identifying strategic partners,fostering mentorship and connection between suppliers,practicing inclusive sourcing,and much more.In 2023,we mentored five diverse-owned suppliers who provide services in different industries,incl

187、uding digital marketing,executive training,and recruiting from the disabled community.Two of these mentees were included in sourcing opportunities.Looking ahead to 2024,we plan to continue this initiative across additional industries.In addition to mentoring diverse-owned suppliers,we engage in dive

188、rse supplier outreach and education activities throughout the year,including hosting webinars and supplier diversity events.Through this intentional approach to supplier diversity,we aim to help drive economic impact,which helps influence positive health outcomes in local communities where our patie

189、nts and colleagues live.Intellectual Property(IP)Pfizers ability to drive science forward and deliver breakthroughs that change patients lives is fueled by the protections provided by the intellectual property system.The patent system plays a crucial role in incentivizing innovation,promoting compet

190、ition,and encouraging collaboration and partnerships,which are essential to scientific progress.By requiring the disclosure of inventions,the patent system facilitates the exchange of knowledge and ideas.It is this combination of incentives and disclosure that empowers companies like Pfizer to inves

191、t significant time,effort,and resources into the discovery,research,and development of groundbreaking medicines that have the potential to transform lives.We are committed to the responsible use of our intellectual property,as reflected in the“IP Principles for Advancing Cures and Therapies”(IP PACT

192、).Recently,Pfizer updated our Patent Policy Position with the aim of enhancing transparency and offering greater clarity regarding our approach to patent filing and enforcement.Our patent filing decisions are based on a number of factors,chief among them whether the invention reflects a genuine inno

193、vation that will ultimately support the needs of patients.To learn more about our patent practices and commitment to access to medicines,please see our Patent Policy Position.We recognize the unique socioeconomic challenges facing Least Developed Countries,as defined by the UN Committee for Developm

194、ent Policy,and have a policy of patent nonenforcement in those countries.This policy extends to our entire portfolio of vaccines and medicines.We have also engaged in a voluntary licensing agreement with the Medicines Patent Pool to help facilitate the production and supply of generic versions of ou

195、r oral COVID-19 treatment.Our efforts here are just one part of how were working to provide equitable access to medicines to the most vulnerable populations.Please see pages 34 and 37 for more information on our Health Equity activities and page 35 for information on our Healthcare Infrastructure in

196、itiatives.In the most recent Access to Medicine Index,Pfizer was recognized as performing“above average”in sharing IP assets with third-party researchers.We also continue to be a sponsor of the Inventor Assistance Program,a World Intellectual Property Organization(WIPO)initiative in cooperation with

197、 the World Economic Forum that matches developing country inventors and small businesses of limited financial means with patent attorneys that provide pro bono legal assistance to secure patent protection.Ethics,Transparency,Quality-continuedPfizer 2023 Impact Report21IntroductionGovernanceSocialEnv

198、ironmentAppendixESG PerformanceGovernanceClinical TrialsOur work in clinical trials is fundamental to achieving our Purpose.Patient health and safety is at the heart of this including how we design,run,and communicate our clinical trial research.Our leadership is committed to ensuring quality and et

199、hical conduct in clinical trials,as is also reflected in our policies and processes.Our conduct is guided with the help and oversight of a variety of groups,including patient organizations,institutional review boards and ethics committees,regulatory authorities,data and safety monitoring boards,and

200、medical and industry association guidelines governing ethical clinical trial conduct and research integrity.In keeping with our core value of Equity,our teams continue to find new ways to remove barriers to clinical trial participation and improve the experience of clinical trial participants,such a

201、s using digital tools,local healthcare providers and settings,and other approaches to make clinical trials more flexible and accessible.This includes adhering to the“plain language results summary”initiative wherein we share information about clinical trial results and descriptions in a more underst

202、andable and accessible way to a general audience.In 2023,we unveiled a new initiative to share certain individual-level clinical trial data with study participants,which has never been done systematically before.These plain-language study results summaries and individual-level clinical trial data ca

203、n be accessed by trial participants through an opt-in clinical trial alumni website at .Additionally,Pfizer provides a number of avenues that allow the general public to learn more about participating in a clinical trial as well as get connected to clinical trial sites near them through a convenient

204、 Find-a-Trial search tool on PfizerClinicalT.Pfizer also launched PfizerL,the first industry-sponsored research registry,which aims to make it easier for interested individuals to find Pfizer clinical trials,helping to address longstanding challenges associated with clinical trial recruitment,and ad

205、vances Pfizers mission of bringing medicines to patients faster.This novel approach allows interested individualseither healthy volunteers or those with medical conditionsto share information about themselves to potentially be matched to an available Pfizer clinical trial with the help of a PfizerLi

206、nk Navigator.All Pfizer-sponsored interventional studies respect study participant rights and patient privacy.Required training for both Pfizer employees and contracted research sites includes a focus on ethical topics.Studies are conducted in accordance with our high ethical standards,applicable la

207、ws and regulations,and principles derived from relevant international standards,including:The Council for International Organizations of Medical Sciences(CIOMS)International Ethical Guidelines The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use(ICH

208、)E6 guideline for Good Clinical Practice PhRMAs Principles on Conduct of Clinical Trials and Communication of Clinical Trial Results The Declaration of Helsinki The U.S.Belmont Report More information on Pfizer policies related to clinical trials can be found here on our research integrity and trans

209、parency page at P.You can also learn more about our clinical trial work at P and by searching“Pfizer”on Clinical Trials.gov.DIVERSITY IN CLINICAL TRIALS Race,ethnicity,age,and gender all impact how people respond to treatment,so it is essential that clinical trial studies reflect the diversity of th

210、e potential recipient population.Pfizer has taken many steps over the years to help ensure diverse representation in clinical trials,including reinforcing the importance of diversity in trials among our clinical study teams.We have also shared our own knowledge and learnings with others because we r

211、ecognize that no single entity can solve the longstanding challenges alone.In 2023,Pfizer published a framework that we use to set enrollment goals to help ensure participant diversity in sponsored clinical trials in the U.S.Weve made a commitment to diverse representation in our clinical trials and

212、 that starts with setting metrics by which to hold ourselves accountable.Data Privacy and Protection We are committed to the responsible,transparent,and secure use of personal data entrusted to us by patients,customers,colleagues,and others.Our privacy practices are governed by our Global Privacy Co

213、mmittee,a cross-functional governance body composed of senior-level leaders who provide oversight and guidance that informs company practices.Additionally,our Global Privacy Office maintains an enterprise-wide policy and standards that guide the collection,maintenance,and protection of personal data

214、 and consider the legal and regulatory requirements where we do business.We also mandate regular colleague and contractor training on global privacy principles in accordance with our commitment to respect and safeguard personal data.We do all of this to help ensure that we are respecting the right t

215、o privacy of individuals and responsibly collecting and managing the data we collect.Additionally,Pfizers Privacy Principles outline our approach to the management,collection,and appropriate uses of personal health data.These principles also cover what we do to help ensure proper safeguards are in p

216、lace to protect what has been entrusted to us.Similarly,Pfizer is committed to the responsible use of artificial intelligence.For more information please see our Policy Position on Artificial Intelligence for how we are setting a clear path for the company to use this technology.Ethics,Transparency,

217、Quality-continuedPfizer 2023 Impact Report22IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceGovernanceHuman Rights and the Right to Health Pfizer is committed to conducting business in an ethical and responsible manner.This includes respecting internationally recognized human rights th

218、roughout our operations,from lab to patient and our diverse global supply chain of numerous local and global third-party vendors.Please see page 19 for more information on Supply Chain Transparency.Throughout 2023 and beyond,we continue to focus on the right to health as our most salient human right

219、s issue,with availability,accessibility,and affordability as key focus areas.Other salient human rights are the principle of nondiscrimination;the right to privacy;freedom from slavery and forced labor and other abuses,including child labor;the right to enjoy just and favorable working conditions;th

220、e right to a safe workplace;and the right to a healthy environment.In line with the UN Guiding Principles on Business and Human Rights,our approach to human rights focuses on risk that could have the most severe impact on people:our patients,our colleagues,the workers of our business partners,and th

221、e communities in which we operate.We strive to keep our policies up-to-date with our work and the evolving external environment.Our latest update reflects our efforts to protect personal data,the right to privacy,and our principles for the responsible use of artificial intelligence.Read more about P

222、fizers commitment to human rights on our website.Political Contributions and Lobbying Activities We understand the impact public policy has on our ability to meet patient needs and provide value to our shareholders.As such,we actively participate in dialogue around public policy with lawmakers and s

223、takeholders to advocate and educate,in addition to explaining our perspectives.We believe that public policy engagement is an important and appropriate role for companies to be engaged with in open societies when conducted in a legal and transparent manner.Our public policy activities focus on helpi

224、ng to build a constructive discourse in the political and regulatory environment while supporting policiesand policymakerswho are aligned with our Purpose and position us to better deliver on these same ideals.It is important to note that Pfizers policy precludes the company from making direct indep

225、endent expenditures in connection with any U.S.federal or state election.Additionally,all corporate political contributions are published in the Pfizer Political Action Committee(PAC)and Corporate Political Contributions Report in compliance with Pfizers corporate policy.Please see the latest report

226、 here.Pfizer is a member of various industry and trade groups that represent both the pharmaceutical industry and the business community at large to bring about consensus on broad policy issues.In addition to trade group positions on healthcare policy issues,we realize these organizations may engage

227、 in a broad range of other issues that extend beyond the scope of what is of primary importance to Pfizers business.If concerns arise about a particular issue,we convey our concerns,as appropriate.We believe there is value in making sure our positions on issues important to patients,Pfizer,and our i

228、ndustry are communicated and understood within those organizations.Pfizer issued a report outlining the public policy positions of Pfizer and key trade associations across six areas of key public policy and ESG significance for Pfizer.The report also compares Pfizer and the trade associations positi

229、ons and describes the degree of alignment and areas of misalignment.Pfizers corporate political contributions and lobbying activities are focused on promoting the interests of the patients we serve and our company,without regard to the personal political preferences or affiliations of any of our col

230、leagues,officers,or board members.The companys corporate political contributions and lobbying activities are subject to robust internal procedures designed to align these efforts with our public policy priorities,applicable law,and patient-centric agenda.The company has an extensive training and rep

231、orting program in place designed to ensure compliance with applicable laws and regulations as well as Pfizers internal standards.Please see here for information on our anti-bribery and anti-corruption program and here for a summary of our Anti-Bribery and Anti-Corruption Policy.RESPONSIBLE TAX PRACT

232、ICESFulfilling our tax responsibilities is not only a legal obligation,but also an important contribution to the communities in which we operate and part of fostering trust.We are committed to abiding by all tax laws in the countries in which we operate and paying all taxes due.We have a zero-tolera

233、nce approach to non-compliance with tax laws.Our Compliance Helpline is available for internal and external parties to raise concerns.Oversight and responsibility for tax matters lies with our Global Tax Department,reporting to our Chief Financial Officer.Our robust policies and proceduresoverseen b

234、y our Board of Directors and Audit Committeeare designed to comply with all applicable laws and regulations,and are regularly reviewed and updated to reflect changing tax landscapes.Consistent with our commitment to sustainable values,we prioritize tax governance,compliance,planning,risk management,

235、and transparency.We maintain constructive relationships with governmental authorities,recognizing the importance of engaging in open and transparent dialogue and acting with integrity.Additional information about Pfizers taxes is disclosed in the notes to our consolidated financial statements,which

236、are subject to independent audit.Ethics,Transparency,Quality-continuedPfizer 2023 Impact Report23IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceGovernanceRight Incentives We aspire to drive positive social and environmental change in our role as a responsible corporate citizen.Our ESG

237、 strategy is designed to leverage compensation as a key motivator to hold ourselves accountable.For the 2023 performance year,the Compensation Committee of the Board selected three social and environmental KPIs for the ESG Scorecard to tie to our annual short-term incentive compensation:1.Percentage

238、 of VP and higher roles held by women(globally)2.Percentage of VP and higher roles held by minorities(U.S.)3.Greenhouse Gas Emissions The goals set for 2023 as part of the Global Performance Plan(GPP)Program were also based on our publicly announced longer term goals in these areas.In addition to be

239、ing objectively measurable and auditable,we believe these ESG Scorecard KPIs are holistic drivers of our future success as a company and are aligned with our strategy.The ESG Scorecard KPIs were factors in evaluating the funding of our GPP Program for over 40,000 eligible global colleagues and leade

240、rs.We plan to continue this approach for the 2024 performance year.Incorporating ESG into our compensation program amplifies our commitment to long-term value creation and sustainability.In addition,ESG factors beyond the three ESG Scorecard KPIs may also be included in an individual executives perf

241、ormance goals.For additional details on the GPP Program,refer to the Pfizer 2024 Proxy Statement.Please see page 41 for more information on our Pay Equity efforts.Board of Directors and Board CommitteesThe Board of Directors is elected annually by the shareholders.The primary responsibility of the B

242、oard is to represent shareholders and to enhance long-term shareholder value.The Board elects the Chairman of the Board,the Chief Executive Officer,and other members of the senior management team and acts as an advisor and counselor to senior management and ultimately monitors its performance.The fu

243、nction of the Board to monitor the performance of senior management is facilitated by the presence of a majority of independent,non-employee Directors who have substantive knowledge of the companys business.The Board has determined that all of our current Directors(other than Dr.Albert Bourla)are in

244、dependent.Pfizers Board Committees are integral to the overall functioning of the Board.The Board has six committees:Audit Committee Compensation Committee Executive Committee Governance&Sustainability Committee Regulatory and Compliance Committee Science and Technology Committee The committees char

245、ters can be viewed on our corporate website at:Board Committee Charters.Board Leadership Structure In December 2023,following a thorough review by the Governance&Sustainability Committee,the independent Directors evaluated the Boards leadership structure taking into consideration the companys perfor

246、mance under the current operating and governance environment,executive leadership changes,and investor feedback.The Committee,with input from the other independent Directors,determined that it would be in the best interest of the company and its shareholders for Dr.Bourla,Pfizers CEO,to continue ser

247、ving as Chairman of the Board in 2024.The Board concluded that Dr.Bourlas deep scientific,industry,and regulatory expertise,along with his extensive company knowledge,helps enable him to effectively lead the Board and execute company strategies.The combined role,coupled with the strong Lead Independ

248、ent Director,enables the Board to exercise its independent oversight and be responsive to challenges and opportunities as they arise.AccountabilityPfizer 2023 Impact Report24IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceGovernanceBoard Diversity and Independence Our Board is composed

249、 entirely of independent directors other than our Chairman and CEO,Albert Bourla,and is diverse.Diversity is defined by gender,age,race,ethnicity,background,professional experience,and perspectives.Each Director provides a unique perspective,experience,and skill set,which creates an effective and we

250、ll-functioning Board.To help ensure effective refreshment and proactively manage eventual vacancies on the Board,the Governance&Sustainability Committee and the full Board consider a diverse pool of qualified director candidates when seeking new Directors.Since 2020,three new Directors have joined P

251、fizers Board,bringing the Boards average tenure to eight years.Shareholders and other stakeholders may communicate with any of our Directors,including the Lead Independent Director and the Audit Committee Chair,as follows:By email:https:/ mail:Office of the Corporate Secretary,Pfizer Inc.,66 Hudson

252、Boulevard East,New York,NY 10001-2192.Board TenureAverage Tenure 10+Years6 to 10 Years0 to 5 YearsBoard DiversityFemaleEthnically Diverse3 of 12 Directors4 of 12 Directors354968 yearsBoard CompositionKey Skills and ExperienceBusiness Leadership and OperationsInternational BusinessMedicine and Scienc

253、eHealthcare and PharmaFinance and AccountingRisk ManagementAcademiaHuman Capital ManagementGovernment and Public PolicyTechnology and Cybersecurity66654433Accountability-continuedTotal Number of Directors on the Board12Pfizer 2023 Impact Report25IntroductionGovernanceSocialEnvironmentAppendixESG Per

254、formanceIntroductionGovernanceSocialEnvironmentAppendixESG PerformanceThe health of our global environment impacts everyone.At Pfizer,we are committed to reducing our environmental footprint.Our company Purpose guides our environmental priorities,with a focus on impact reduction,conservation of reso

255、urces,and the minimization of waste arising from our operations.Environment26-Climate ChangeReducing Emissions from Our OperationsProactive External EngagementUnderstanding How Climate Change Could Impact Our BusinessAccelerating Action Across Our Supply Chain29-Sustainable MedicinePharmaceuticals i

256、n the EnvironmentWasteWater StressBiodiversityHow our approach to environmental sustainability supports the Sustainable Development GoalsIndustry,Innovation,and InfrastructureWe promote resilient and sustainable infrastructure,scientificresearch and innovation.Responsible Consumption and ProductionW

257、e aim to achieve environmentally sound life cyclemanagement and adopt sustainable practices.Climate ActionThrough our goals we are taking urgent action to help combatclimate change and its impacts.More information on the SDGs here.Pfizer 2023 Impact Report26IntroductionGovernanceSocialEnvironmentApp

258、endixESG PerformanceEnvironmentWe recognize global climate change as one of the defining issues of our time,requiring collective action to mitigate the potential risks it poses.Such risks include the potential for increased adverse impacts on human health and decreased access to critical medicines a

259、nd vaccines due to disruptions in value chains caused by the greater frequency of severe weather.Pfizer is continuing its near-term commitment to reduce company greenhouse gas(GHG)emissions by 46%compared with a 2019 baseline,aligned with a 1.5C trajectory,and to drive action by encouraging supplier

260、s to also set science-based GHG emissions reduction goals.We have further committed to reduce GHG emissions by working to achieve the voluntary Net Zero Standard by 2040,ten years earlier than the timeline described in the standard.By 2040 Pfizer aims to decrease its company GHG emissions by 95%and

261、its value chain emissions by 90%from 2019 levels by reducing the energy demand of our operations,transitioning away from fossil fuels,sourcing renewable electricity,and engaging suppliers to catalyze equivalent action.We are also pursuing Science Based Targets initiative(SBTi)validation of our Net Z

262、ero target.Pfizer was one of the initial signatories to the U.S.Department of Health and Human Services(HHS)climate pledge.The pledge,launched in 2022,calls on stakeholders in the U.S.healthcare systemincluding hospitals,health systems,payers,suppliers,and pharmaceutical companiesto reduce GHG emiss

263、ions and build a more climate resilient healthcare infrastructure.By signing,we committed to reduce GHG emissions,publicly report our progress,and develop a climate resiliency plan.Climate ChangeTargetProgressReducing Scope 1 and 2 GHG emissions by 46%from a 2019 baseline by 2030Scope 1 and 2 GHG em

264、issions in 2023 were 3.5%lower than 2022.Emissions for 2023 were 13.9%lower than the 2019 baseline.Sourcing 80%of electricity from renewables by 2025,and 100%by 2030Pfizer sourced 10%renewable electricity in 2023.Pfizer has entered into virtual power purchase agreements(VPPA)covering North America a

265、nd the EU.These projects,expected to come online in 2025,will cover approximately 68%of Pfizers electricity needs(as measured against 2023 electricity consumption).Reducing emissions from upstream transportation and distribution by 10%and from business travel by 25%by 2025 from a 2019 baselineEmissi

266、ons associated with upstream transportation and distribution were 31%lower than in 2022 and 22%higher than the 2019 baseline.We continue to look for opportunities to move product shipments from air to ocean and are working with our logistics providers to transition to low emission fuels and vehicles

267、 where possible.Travel-related GHG emissions were 55%lower than the 2019 baseline.We have implemented tools to help business travelers make informed decisions about travel options.This includes using digital tools to limit travel and using preferred carriers that are advancing GHG reduction targets.

268、Working to accelerate change across our supply chain,driving 64%of our suppliers of goods and services by spend to also set science-based GHG emission reduction goals by 2025Currently 51%of our suppliers by spend have or have committed to develop science-based GHG emissions reduction targets.Environ

269、mental data included in this report may include certain estimates and assumptions given data availability at the time of publication.Our finalized 2023 data with additional details will be published on Pfizers Environmental Sustainability page.Does not include Seagan Inc.data.Pfizer aims to achieve

270、a 95%reduction in company(Scope 1 and 2)GHG emissions and a 90%reduction in value chain(Scope 3)emissions by 2040,compared to our 2019 baseline.Our near-term targets are outlined below:Pfizer 2023 Impact Report27IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceEnvironmentReducing Emissi

271、ons from Our OperationsAs part of our efforts to reduce our overall environmental footprint globally,our manufacturing and R&D sites are aligning their environmental sustainability masterplans with our 2040 Net Zero ambition.We seek opportunities to design new facilities or renovation projects with

272、reduced environmental impact(such as energy consumption,water usage,and waste management)so we can reduce resource demand.For example,a new utilities building at our Kalamazoo,Michigan,location received LEED certification;a new manufacturing building at our site in Newbridge,Ireland,was awarded LEED

273、 Silver;and our New York headquarters received LEED Platinum certification.In 2023,Pfizer adopted the My Green Labs(MGL)Certification program at our Cambridge,Massachusetts,site to facilitate engagement of laboratory-based colleagues in environmental stewardship with the aim of accelerating GHG emis

274、sions reductions in our R&D operations.The MGL Certification program has been recognized by the UN Race to Zero campaign as a key measure of progress toward a zero carbon future.A total of 19 laboratories across five of Pfizers research sites in Cambridge,Massachusetts,Boulder,Colorado,Groton,Connec

275、ticut,Pearl River,New York,and Andover,Massachusetts,received MGL Certifications in 2023.Pfizer invests in no-/low-carbon technologies at our sites and through power purchase agreements(PPAs)that enable sourcing of renewable energy.In 2023,we signed virtual PPAs(VPPAs)for four new solar projects in

276、Spain that will collectively cover all of Pfizers purchased electricity in the European Union.These EU VPPAs,along with the North America VPPA we signed in 2021,are key steps in our plan to achieve our RE100 goal of 100%renewable energy by 2030 and the voluntary Net Zero Standard by 2040.When the No

277、rth America and EU VPPA solar projects come online,they are expected to cover approximately 68%of Pfizers global electricity needs as measured against 2023 electricity consumption.Pfizers fleet of vehicles,the majority of which are used by our commercial teams to facilitate education and engagement

278、with healthcare providers,accounted for approximately 0.5%of our total Scope 1 and 2 GHG emissions in 2023.Pfizer is working to advance fleet sustainability through transitioning to battery electric vehicles(BEV)and,where feasible,other low-emission vehicle options,and by supporting fuel management

279、and efficient driving choices for internal combustion vehicles until they can be retired.Our transition to BEV has started in nine markets,with 437 BEVs currently in use and an additional 40 BEVs ordered.We plan to expand BEV implementation to additional markets in 2024 and beyond.Proactive External

280、 Engagement Tackling climate change requires action from all parties across all sectors,and Pfizer urges governments both in the U.S.and abroad to establish ambitious climate policies to stabilize global temperature rise at 1.5C.For additional information on Pfizers climate action program,please see

281、 our:Climate Change Position Statement 2023 CDP Climate Change ResponseUnderstanding How Climate Change Could Impact Our Business We are committed to transparency in evaluating the risks and opportunities that climate change may present to our business.To meet this commitment,we incorporate the Task

282、 Force on Climate-Related Financial Disclosures(TCFD)framework into our ERM governance process and voluntarily report climate-related risks and opportunities.See our TCFD Report on page 76.Climate Change-continuedPfizer 2023 Impact Report28IntroductionGovernanceSocialEnvironmentAppendixESG Performan

283、ceEnvironmentAccelerating Action Across Our Supply ChainRecognizing that our Scope 3(value chain)GHG footprint is approximately four times that associated with our direct operations,Pfizer has been driving action throughout our value chain to help address the complex threat of climate change.Procure

284、ment of goods and services,which is essential to producing medicines and vaccines,is the most significant contributor to our Scope 3 emissions.We therefore expect all our suppliers to commit to ambitious,science-based GHG reduction targets and have integrated environmental criteria in our supplier s

285、ourcing,contracting,and performance management processes.In 2023 we conducted a virtual supplier summit to communicate our expectations and provide resources to assist suppliers in progressing climate action.To support suppliers in their decarbonization journey,we encouraged energy PPA education thr

286、ough the Energize program and offered sponsorships for the Activate program,a collective initiative that targets sustainability/GHG emission improvements at active pharmaceutical ingredient(API)suppliers including Contract Manufacturing Organizations.As a result of our engagement efforts,51%of our s

287、uppliers of goods and services by spend have committed to science-based emission reduction targets,an increase of 22%compared to 2022.We have also continued to make progress in reducing emissions associated with upstream transportation and distribution.We worked internally to educate over 1,500 logi

288、stics colleagues on environmental sustainability principles and to improve data and analytics across all markets where Pfizer operates.We continued to transition shipments from air to ocean where possible and engaged with our third-party logistics providers to identify and invest in opportunities to

289、 use low emission fuels and vehicles to deliver our medicines to markets around the world.We began working with one of our transporters to pilot the use of electric trucks to decarbonize shipments in some U.S.markets and are working to decarbonize all full truckload shipments within Europe.SUPPLIER

290、ENGAGEMENT RECOGNITIONPfizer has been recognized by CDP as a Supplier Engagement Leader for six consecutive years for our work to reduce environmental risks in our supply chain.Climate Change-continuedPfizer 2023 Impact Report29IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceEnvironmen

291、tPfizer has a long history of using the concepts of green chemistry and promoting them across the industry.Through scientific innovation we strive to design more efficient processes that can reduce the environmental impact of our medicines throughout the product life cycle.To expand on this,we are i

292、ntegrating sustainable product design principles within our R&D processes.We aim to positively impact our environmental performance by systematically conserving energy,reducing water and raw materials usage,driving out waste,and embracing circular solutions where possible.The principles also serve t

293、o educate and inform our colleagues,define key metrics and performance targets,and encourage innovation through collaboration and partnerships.In 2022,we began conducting representative life cycle assessments(LCAs)for small molecules,large molecules,vaccines,and devices to help identify those aspect

294、s of the development process that present the greatest opportunity for impact reduction.We progressed a number of LCAs in 2023,including the first for an mRNA vaccine,to add to our understanding of the impact of our products.The data generated from these assessments is shared with our scientists,res

295、earchers,and engineers to help support sustainable innovation and impact reduction.In 2023,Pfizer joined a consortium with seven other pharmaceutical peers to establish a consistent framework for conducting LCAs of pharmaceutical products,aimed at defining environmental product category rules for me

296、dicines,potentially for a publicly available standard.Pharmaceuticals in the Environment Pharmaceuticals in the environment and antimicrobial resistance(AMR)continue to be important environmental issues for our industry.Pfizer is committed to limiting discharge of APIs to wastewater from our manufac

297、turing processes using environmental risk assessment methodologies and emission control practices and technologies.As an active member,Pfizer follows the best practices in the AMR Industry Alliances(AMRIA)Antibiotic Manufacturing Standard.We are working toward our goal of achieving the industry publ

298、ished targets(Predicted No Effect Concentrations)for antibiotics by 2025 and are piloting innovative wastewater management and treatment practices at several sites to advance our management of wastewater discharges.In 2023,Pfizer continued to participate in the development of the certification progr

299、am designed to demonstrate implementation of AMRIAs Antibiotic Manufacturing Standard through an independent third-party certification body.In collaboration with BSI Standards Limited,Pfizer participated in assessments to pilot the certification process at one of our API manufacturing sites and one

300、of our contract manufacturer antibiotic drug product sites.These assessments indicated compliance with the AMRIA Standard and both sites were recommended for certification.Additionally,learnings from these pilots were used to shape the certification program,which officially launched in June 2023.Pfi

301、zer is pursuing opportunities with our internal network,suppliers,and contract manufacturers to implement certification of our antibiotic products.Our efforts to promote adherence to voluntary discharge limits across our supply chain were recognized in a report published by the Access to Medicine Fo

302、undation that assesses steps that pharmaceutical manufacturers are taking to curb the development and spread of AMR(AMR Report on Responsible Manufacturing,August 2023).WasteCentral to our sustainable medicines program is the minimization of waste across our sites globally.We pursue process improvem

303、ents in our research,development,and manufacturing operations through next-generation design projects and the implementation of green chemistry and other sustainability practices.Pfizer sites are expected to consistently seek opportunities to reduce,reuse,repurpose,and recycle materials such as pack

304、aging and plastics.We use an internal performance metric based on hierarchy of control principles(avoid,reduce,reuse,recycle,dispose)to drive waste handling decisions and promote minimization.In 2023,we introduced an initiative to minimize waste sent to landfill from our manufacturing sites.We demon

305、strated our objective of landfill avoidance by sending the approximately 8.6 million kilograms of waste resulting from the July 2023 tornado that impacted our Rocky Mount,North Carolina,site to waste-to-energy facilities.Since 2019,we have reduced the quantity of waste from routine operations sent t

306、o landfill by over 5.4 million kilograms.Pfizer participates in the Pharmaceutical Product Stewardship Work Group(PPSWG)in the U.S.and MEDSdisposal in Europe to help enable proper disposal of unused medicines.Sustainable MedicinesPfizer 2023 Impact Report30IntroductionGovernanceSocialEnvironmentAppe

307、ndixESG PerformanceEnvironmentWater Stress The availability of and access to clean water is a basic human need globally that must be addressed locally.Pfizers Water Stewardship position statement describes our commitment to being good stewards of the water we use to make medicines and vaccines,parti

308、cularly in water-stressed areas.To this end,we completed water stress assessments at all Pfizer sites to identify water quality,scarcity,and availability risks across our network and are developing action plans for sites with elevated risk scores.These plans include elements such as quantifying wate

309、r use,implementing mitigation plans and establishing water conservation targets,protecting water quality,improving wastewater treatment where necessary,evaluating recycling practices,and engaging with surrounding communities.We will measure progress at our internal sites while engaging with our key

310、suppliers in water-stressed areas to encourage them to develop and implement similar action plans.BiodiversityPfizer is evaluating our potential impacts and dependencies on nature and biodiversity to further our understanding and address growing stakeholder expectations.In 2023,we completed biodiver

311、sity risk assessments for our manufacturing and R&D sites and are developing mitigation plans for sites located in sensitive areas as defined by the World Wildlife Fund Biodiversity Risk Filter tool to minimize the impacts of our operations on local habitats and native species.Several of our sites h

312、ave active biodiversity teams who work with local communities on a variety of habitat restoration and conservation activities appropriate to the local surroundings,including dedicating areas to biodiversity improvements and preservation.In 2023,we introduced an internal initiative to increase native

313、 biodiversity on sites undergoing significant construction or renovation,including by working with local ecologists and consultants to create biodiversity and habitat improvement strategies.Sustainable Medicines-continuedPfizer 2023 Impact Report31IntroductionGovernanceSocialEnvironmentAppendixESG P

314、erformanceIntroductionGovernanceSocialEnvironmentAppendixESG PerformanceAt Pfizer,our Purpose is rooted in achieving social good.We know that when we succeed,our breakthroughs can potentially have life-changing effects.We aim to address illnesses from widespread infectious diseases to conditions wit

315、h historically unmet need.Pfizer is mindful of the urgency of our mission,as the world fights against the spread of deadly new diseases and struggles with inequities in health outcomes among populations.Our goal is to leverage partnerships and programs to allow quick and widespread access to our bre

316、akthrough medicines and vaccines around the world.Social32-Innovation and Global HealthProduct InnovationOur Innovations are Guided by Patient Needs34-Equitable Access and PricingHealthcare InfrastructureGlobal Health System StrengtheningProduct Donations Patient Centricity38-Our PeopleColleague Eng

317、agementGrowth and DevelopmentHealth,Safety,and Well-beingColleague WellnessDiversity,Equity,and Inclusion(DEI)PartnershipsEnterprise Colleague Resource GroupsPay EquityOpportunity Parity External RecognitionHow our approach to social issues supports the SDGsGood Health and Well-BeingWe aspire to ens

318、ure health and well-being for all at all ages through equitable access to medicines and vaccines.Gender EqualityWe aim to end discrimination against women,ensure equalopportunities for leadership and access to reproductive health.Decent Work and Economic GrowthWe promote inclusive and sustainable ec

319、onomic growth,employment,and decent and safe working environments.Reduced InequalitiesWe empower and promote the social and economic inclusion of all,irrespective of age,sex,disability,race,ethnicity,origin,religion oreconomic or other status.Partnerships for the GoalsWe are working to create new pa

320、rtnerships to help attain relevantsustainable development goals.More information on the SDGs here.Pfizer 2023 Impact Report32IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceSocialAs the global health landscape continues to evolve,so do we,making innovation one of our greatest tools as

321、we aim to uncover new combinations,designs,and advances to help address an array of challenges.But medicinal solutions are only part of the equation:getting vaccines and therapies to patients who need them,regardless of location,requires innovation in delivery systems.Pfizer focuses on both aspects

322、of innovation by investing in the right people and partnerships.Pfizer colleagues continue to break barriers in the discovery and delivery of treatments and solutions with a relentless focus on providing for underserved and vulnerable communities around the world.Our strategic public and private par

323、tnerships allow for reach and scale when key players are brought together.Product Innovation At Pfizer,we measure ourselves by our pursuit of breakthroughs that change patients lives.This means prioritizing innovation and accelerating our efforts to bring solutions to those who need them.Our acquisi

324、tion of Seagen Inc.helps position us to accelerate the next generation of breakthrough treatments for people with cancer.Looking ahead,our current pipeline as of January 30,2024,consists of 1121 programs in development(from Phase 1 through registration)and reflects how we empower our scientists to w

325、ork efficiently and with an emphasis on quality.Reduced cycle times,while continuing our focus on safety and quality,can help get our breakthroughs to patients faster,potentially addressing more unmet needs.In 2023,we achieved an end-to-end success rate of 17%from first-in-human(FIH)to approval at a

326、 new molecular entity(NME)levelwhich is nearly 10 times our 2010 performance.Our Purpose Blueprint sets forth a new ambition to change a billion lives a year by 2027.This ambition focuses on the patient and how many lives we can impact.Our core business principles recognize that Time is Life,encoura

327、ging us to develop medicines at lightspeed,and that Trust is Everything,continuing to prioritize quality,safety,and integrity.DIGITAL INNOVATIONGreater social impact is the result of our focus on excellence and productivity as we get more life-changing medicines into the hands of patients at a faste

328、r rate.Pfizer responsibly leverages digital,data,artificial intelligence,and machine learning as a complement to human insights to accelerate innovation in the interest of patients at every stepfrom discovery to clinical development,manufacturing,distribution,and commercializationand to enable our c

329、linical,logistics,and other experts across the business to spend more of their efforts developing and delivering breakthroughs that change patients lives.Innovation and Global Health1 Includes Seagen Inc.data.Pfizer 2023 Impact Report33IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceSo

330、cialOur Innovations are Guided by Patient Needs We are focused on advancing science and innovation for patients in therapeutic areas including the following:OncologyPfizer has deep scientific and biologic understanding in oncology,the study and treatment of cancer,which impacts millions of lives eve

331、ry year.Pfizers acquisition of Seagen Inc.demonstrates our commitment to discovering and developing medicines that significantly improve and extend the lives of people with cancer.As an example,we are proud to focus on treatment for multiple myeloma(MM),an aggressive and currently incurable blood ca

332、ncer that affects plasma cells made in the bone marrow.MM is the second most common type of blood cancer,with over 35,000 new cases diagnosed annually in the U.S.and 176,000 globally.Vaccines Pfizer is working to deliver breakthroughs in vaccines against invasive pneumococcal disease in infants and

333、children and against respiratory syncytial virus(RSV).RSV is a contagious virus that can be dangerous for infants and older adults and can cause severe respiratory infections.Alopecia Areata We look forward to seeing how our work may transform the lives of those who live with severe alopecia areata,an autoimmune disease characterized by patchy or complete hair loss on the scalp,face,or body.This d